Improved glycemic status, insulin resistance and inflammation after receiving oral oleoylethanolamide supplement in people with prediabetes: a randomized controlled trial

Table 1 The comparison of baseline characteristics of the participants

Variable	Mean ± SD Placebo (n = 21)	Mean ± SD Oleoylethanolamide (n = 22)	P1
Age (years)	49.76 ± 8.10	49.64 ± 7.93	0.529
Height (cm)	163.71 ± 9.12	162.43 ± 10.59	0.614
Weight (kg)
Before	73.55 ± 8.99	71.83 ± 7.89	0.512
After	72.63 ± 10.37	70.49 ± 11.33	0.419
P2	0.58	0.61
Body mass index (K g/m²)
Before	27.44 ± 1.9	27.22 ± 1.07	0.329
After	27.09 ± 1.26	26.71 ± 1.1	0.307
P2	0.3	0.291
Physical activity (met-h/week)
Before	38.19 ± 5.48	39.02 ± 8.25	0.39
After	39.06 ± 6.11	40.66 ± 9.11	0.402
P2	0.404	0.41
Metformin dose (mg)	1023 ± 206.07	1040.25 ± 219.17	0.63

Data are expressed as means ± SD
P1: Mean comparison of the baseline characteristics between the two groups of OEA and placebo (Independent samples t-test)
P2: Mean comparison of the baseline characteristics in each group at baseline and end of study (Paired samples t-test)

ISSN: 1758-5996